Acute Coronary Syndrome Market is segmented By Clinical Development Phase (Late-stage Products (Phase III), Mid-stage Products (Phase II), Early-stage Products (Phase I), ....
Market Size in USD
CAGR7.1%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 7.1% |
Market Concentration | Low |
Major Players | DalCor Pharmaceuticals, Novartis Pharmaceuticals, Genentech, Sanofi |
The Global Acute Coronary Syndrome Market is estimated to be valued at USD 13.1 Bn in 2024 and is expected to reach USD 26.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031. The market is driven by increasing prevalence of cardiovascular diseases, growing geriatric population, rising levels of obesity and a sedentary lifestyle.
The market is witnessing positive trends with advanced diagnostic technologies helping in early diagnosis and increasing awareness about heart diseases among people. Manufacturers are investing heavily in research and development of innovative drugs and devices for treatment of acute coronary syndrome. Several new drug launches and pipeline products are expected to enter the market in coming years, further propelling market growth.